Zdrowie i gospodarka · 30/04/2010

FDA Announces Guidance for Blood Donors Deferred Due to False Positive Hepatitis B Test Results

The Food and Drug Administration (FDA) has released a guidance document providing recommendations for reentering blood donors who were previously deferred due to false positive test results for antibodies to hepatitis B core antigen (anti-HBc). The guidance utilizes FDA-licensed hepatitis B virus nucleic acid tests (HBV NAT) to determine whether a donor is truly infected with hepatitis B virus (HBV).